BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19012507)

  • 1. Reovirus therapy in cancer: has the orphan virus found a home?
    Yap TA; Brunetto A; Pandha H; Harrington K; Debono JS
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1925-35. PubMed ID: 19012507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic viral therapy using reovirus.
    Thirukkumaran C; Morris DG
    Methods Mol Biol; 2009; 542():607-34. PubMed ID: 19565924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reovirus: Rationale and clinical trial update.
    Lal R; Harris D; Postel-Vinay S; de Bono J
    Curr Opin Mol Ther; 2009 Oct; 11(5):532-9. PubMed ID: 19806501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reovirus-based therapy for cancer.
    Kelly K; Nawrocki S; Mita A; Coffey M; Giles FJ; Mita M
    Expert Opin Biol Ther; 2009 Jul; 9(7):817-30. PubMed ID: 19527106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.
    Stoeckel J; Hay JG
    Curr Opin Mol Ther; 2006 Jun; 8(3):249-60. PubMed ID: 16774045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus.
    Zhao X; Chester C; Rajasekaran N; He Z; Kohrt HE
    Mol Cancer Ther; 2016 May; 15(5):767-73. PubMed ID: 27197256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Viral Therapy Using Reovirus.
    Thirukkumaran C; Morris DG
    Methods Mol Biol; 2015; 1317():187-223. PubMed ID: 26072409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reovirus - possible therapy of cancer.
    Figova K; Hrabeta J; Eckschlager T
    Neoplasma; 2006; 53(6):457-62. PubMed ID: 17167712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.
    Kapadia R; Coffey MC
    Methods; 2010 Dec; 52(4):301-6. PubMed ID: 20801221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer.
    Shmulevitz M; Marcato P; Lee PW
    Oncogene; 2005 Nov; 24(52):7720-8. PubMed ID: 16299532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.
    Harrington KJ; Vile RG; Melcher A; Chester J; Pandha HS
    Cytokine Growth Factor Rev; 2010; 21(2-3):91-8. PubMed ID: 20223697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
    Heinemann L; Simpson GR; Boxall A; Kottke T; Relph KL; Vile R; Melcher A; Prestwich R; Harrington KJ; Morgan R; Pandha HS
    BMC Cancer; 2011 Jun; 11():221. PubMed ID: 21645351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection.
    Bourhill T; Mori Y; Rancourt DE; Shmulevitz M; Johnston RN
    Viruses; 2018 Aug; 10(8):. PubMed ID: 30103501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.
    Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J
    Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.
    Rodríguez Stewart RM; Berry JTL; Berger AK; Yoon SB; Hirsch AL; Guberman JA; Patel NB; Tharp GK; Bosinger SE; Mainou BA
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.
    Carew JS; Espitia CM; Zhao W; Kelly KR; Coffey M; Freeman JW; Nawrocki ST
    Cell Death Dis; 2013 Jul; 4(7):e728. PubMed ID: 23868061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture.
    Shmulevitz M; Lee PW
    Methods Mol Biol; 2012; 797():163-76. PubMed ID: 21948476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
    Kolb EA; Sampson V; Stabley D; Walter A; Sol-Church K; Cripe T; Hingorani P; Ahern CH; Weigel BJ; Zwiebel J; Blaney SM
    Pediatr Blood Cancer; 2015 May; 62(5):751-8. PubMed ID: 25728527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts.
    Hingorani P; Zhang W; Lin J; Liu L; Guha C; Kolb EA
    Cancer; 2011 Apr; 117(8):1764-74. PubMed ID: 21472724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noncanonical Cell Death Induction by Reassortant Reovirus.
    Rodríguez Stewart RM; Raghuram V; Berry JTL; Joshi GN; Mainou BA
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.